 | • レポートコード：MRC23Q35751 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、88ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の急性リンパ芽球検査市場について調査・分析し、世界の急性リンパ芽球検査市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（Bリンパ球検査、Tリンパ球検査、その他）、用途別セグメント分析（臨床検査室、病院、学術・研究機関、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、DrLal Path Labs、Bio-Rad Lab、Qiagen、Invivoscribe、Illumina、ArcherDx、Asuragen、Adaptive Biotechnologies、NeoGenomics Lab、Laboratory Corporation of America Holdings、ARUP Labなどが含まれています。世界の急性リンパ芽球検査市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、急性リンパ芽球検査市場規模を推定する際に考慮しました。本レポートは、急性リンパ芽球検査の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、急性リンパ芽球検査に関するビジネス上の意思決定に役立てることを目的としています。 ・急性リンパ芽球検査市場の概要 - 急性リンパ芽球検査のタイプ別セグメント - 世界の急性リンパ芽球検査市場規模：タイプ別分析（Bリンパ球検査、Tリンパ球検査、その他） - 急性リンパ芽球検査の用途別セグメント - 世界の急性リンパ芽球検査市場規模：用途別分析（臨床検査室、病院、学術・研究機関、その他） - 世界の急性リンパ芽球検査市場規模予測（2018年-2029年） ・急性リンパ芽球検査市場の成長トレンド - 急性リンパ芽球検査の地域別市場規模（2018年-2029年） - 急性リンパ芽球検査市場ダイナミクス - 急性リンパ芽球検査の業界動向 - 急性リンパ芽球検査市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：Bリンパ球検査、Tリンパ球検査、その他 - 世界の急性リンパ芽球検査のタイプ別市場規模（2018年-2023年） - 世界の急性リンパ芽球検査のタイプ別市場規模（2024年-2029年） ・用途別セグメント：臨床検査室、病院、学術・研究機関、その他 - 世界の急性リンパ芽球検査の用途別市場規模（2018年-2023年） - 世界の急性リンパ芽球検査の用途別市場規模（2024年-2029年） ・急性リンパ芽球検査の地域別市場規模 - 北米の急性リンパ芽球検査市場規模（2018年-2029年） - アメリカの急性リンパ芽球検査市場規模（2018年-2029年） - ヨーロッパの急性リンパ芽球検査市場規模（2018年-2029年） - アジア太平洋の急性リンパ芽球検査市場規模（2018年-2029年） - 中国の急性リンパ芽球検査市場規模（2018年-2029年） - 日本の急性リンパ芽球検査市場規模（2018年-2029年） - 韓国の急性リンパ芽球検査市場規模（2018年-2029年） - インドの急性リンパ芽球検査市場規模（2018年-2029年） - オーストラリアの急性リンパ芽球検査市場規模（2018年-2029年） - 中南米の急性リンパ芽球検査市場規模（2018年-2029年） - 中東・アフリカの急性リンパ芽球検査市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 DrLal Path Labs、Bio-Rad Lab、Qiagen、Invivoscribe、Illumina、ArcherDx、Asuragen、Adaptive Biotechnologies、NeoGenomics Lab、Laboratory Corporation of America Holdings、ARUP Lab ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Acute Lymphoblastic Testing market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Acute Lymphoblastic Testing is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Acute Lymphoblastic Testing is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Acute Lymphoblastic Testing in Clinical Laboratories is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Acute Lymphoblastic Testing include DrLal Path Labs, Bio-Rad Lab, Qiagen, Invivoscribe, Illumina, ArcherDx, Asuragen, Adaptive Biotechnologies and NeoGenomics Lab, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Acute Lymphoblastic Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Lymphoblastic Testing.
The Acute Lymphoblastic Testing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Acute Lymphoblastic Testing market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acute Lymphoblastic Testing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
DrLal Path Labs
Bio-Rad Lab
Qiagen
Invivoscribe
Illumina
ArcherDx
Asuragen
Adaptive Biotechnologies
NeoGenomics Lab
Laboratory Corporation of America Holdings
ARUP Lab
Segment by Type
B lymphocytes Testing
T lymphocyte Testing
Others
Segment by Application
Clinical Laboratories
Hospitals
Academic and Research Institutes
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Acute Lymphoblastic Testing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Acute Lymphoblastic Testing Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 B lymphocytes Testing
1.2.3 T lymphocyte Testing
1.2.4 Others
1.3 Market by Application
1.3.1 Global Acute Lymphoblastic Testing Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Clinical Laboratories
1.3.3 Hospitals
1.3.4 Academic and Research Institutes
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Acute Lymphoblastic Testing Market Perspective (2018-2029)
2.2 Acute Lymphoblastic Testing Growth Trends by Region
2.2.1 Global Acute Lymphoblastic Testing Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Acute Lymphoblastic Testing Historic Market Size by Region (2018-2023)
2.2.3 Acute Lymphoblastic Testing Forecasted Market Size by Region (2024-2029)
2.3 Acute Lymphoblastic Testing Market Dynamics
2.3.1 Acute Lymphoblastic Testing Industry Trends
2.3.2 Acute Lymphoblastic Testing Market Drivers
2.3.3 Acute Lymphoblastic Testing Market Challenges
2.3.4 Acute Lymphoblastic Testing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Acute Lymphoblastic Testing Players by Revenue
3.1.1 Global Top Acute Lymphoblastic Testing Players by Revenue (2018-2023)
3.1.2 Global Acute Lymphoblastic Testing Revenue Market Share by Players (2018-2023)
3.2 Global Acute Lymphoblastic Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Acute Lymphoblastic Testing Revenue
3.4 Global Acute Lymphoblastic Testing Market Concentration Ratio
3.4.1 Global Acute Lymphoblastic Testing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Acute Lymphoblastic Testing Revenue in 2022
3.5 Acute Lymphoblastic Testing Key Players Head office and Area Served
3.6 Key Players Acute Lymphoblastic Testing Product Solution and Service
3.7 Date of Enter into Acute Lymphoblastic Testing Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Acute Lymphoblastic Testing Breakdown Data by Type
4.1 Global Acute Lymphoblastic Testing Historic Market Size by Type (2018-2023)
4.2 Global Acute Lymphoblastic Testing Forecasted Market Size by Type (2024-2029)
5 Acute Lymphoblastic Testing Breakdown Data by Application
5.1 Global Acute Lymphoblastic Testing Historic Market Size by Application (2018-2023)
5.2 Global Acute Lymphoblastic Testing Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Acute Lymphoblastic Testing Market Size (2018-2029)
6.2 North America Acute Lymphoblastic Testing Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Acute Lymphoblastic Testing Market Size by Country (2018-2023)
6.4 North America Acute Lymphoblastic Testing Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Acute Lymphoblastic Testing Market Size (2018-2029)
7.2 Europe Acute Lymphoblastic Testing Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Acute Lymphoblastic Testing Market Size by Country (2018-2023)
7.4 Europe Acute Lymphoblastic Testing Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Acute Lymphoblastic Testing Market Size (2018-2029)
8.2 Asia-Pacific Acute Lymphoblastic Testing Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Acute Lymphoblastic Testing Market Size by Region (2018-2023)
8.4 Asia-Pacific Acute Lymphoblastic Testing Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Acute Lymphoblastic Testing Market Size (2018-2029)
9.2 Latin America Acute Lymphoblastic Testing Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Acute Lymphoblastic Testing Market Size by Country (2018-2023)
9.4 Latin America Acute Lymphoblastic Testing Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Acute Lymphoblastic Testing Market Size (2018-2029)
10.2 Middle East & Africa Acute Lymphoblastic Testing Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Acute Lymphoblastic Testing Market Size by Country (2018-2023)
10.4 Middle East & Africa Acute Lymphoblastic Testing Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 DrLal Path Labs
11.1.1 DrLal Path Labs Company Detail
11.1.2 DrLal Path Labs Business Overview
11.1.3 DrLal Path Labs Acute Lymphoblastic Testing Introduction
11.1.4 DrLal Path Labs Revenue in Acute Lymphoblastic Testing Business (2018-2023)
11.1.5 DrLal Path Labs Recent Development
11.2 Bio-Rad Lab
11.2.1 Bio-Rad Lab Company Detail
11.2.2 Bio-Rad Lab Business Overview
11.2.3 Bio-Rad Lab Acute Lymphoblastic Testing Introduction
11.2.4 Bio-Rad Lab Revenue in Acute Lymphoblastic Testing Business (2018-2023)
11.2.5 Bio-Rad Lab Recent Development
11.3 Qiagen
11.3.1 Qiagen Company Detail
11.3.2 Qiagen Business Overview
11.3.3 Qiagen Acute Lymphoblastic Testing Introduction
11.3.4 Qiagen Revenue in Acute Lymphoblastic Testing Business (2018-2023)
11.3.5 Qiagen Recent Development
11.4 Invivoscribe
11.4.1 Invivoscribe Company Detail
11.4.2 Invivoscribe Business Overview
11.4.3 Invivoscribe Acute Lymphoblastic Testing Introduction
11.4.4 Invivoscribe Revenue in Acute Lymphoblastic Testing Business (2018-2023)
11.4.5 Invivoscribe Recent Development
11.5 Illumina
11.5.1 Illumina Company Detail
11.5.2 Illumina Business Overview
11.5.3 Illumina Acute Lymphoblastic Testing Introduction
11.5.4 Illumina Revenue in Acute Lymphoblastic Testing Business (2018-2023)
11.5.5 Illumina Recent Development
11.6 ArcherDx
11.6.1 ArcherDx Company Detail
11.6.2 ArcherDx Business Overview
11.6.3 ArcherDx Acute Lymphoblastic Testing Introduction
11.6.4 ArcherDx Revenue in Acute Lymphoblastic Testing Business (2018-2023)
11.6.5 ArcherDx Recent Development
11.7 Asuragen
11.7.1 Asuragen Company Detail
11.7.2 Asuragen Business Overview
11.7.3 Asuragen Acute Lymphoblastic Testing Introduction
11.7.4 Asuragen Revenue in Acute Lymphoblastic Testing Business (2018-2023)
11.7.5 Asuragen Recent Development
11.8 Adaptive Biotechnologies
11.8.1 Adaptive Biotechnologies Company Detail
11.8.2 Adaptive Biotechnologies Business Overview
11.8.3 Adaptive Biotechnologies Acute Lymphoblastic Testing Introduction
11.8.4 Adaptive Biotechnologies Revenue in Acute Lymphoblastic Testing Business (2018-2023)
11.8.5 Adaptive Biotechnologies Recent Development
11.9 NeoGenomics Lab
11.9.1 NeoGenomics Lab Company Detail
11.9.2 NeoGenomics Lab Business Overview
11.9.3 NeoGenomics Lab Acute Lymphoblastic Testing Introduction
11.9.4 NeoGenomics Lab Revenue in Acute Lymphoblastic Testing Business (2018-2023)
11.9.5 NeoGenomics Lab Recent Development
11.10 Laboratory Corporation of America Holdings
11.10.1 Laboratory Corporation of America Holdings Company Detail
11.10.2 Laboratory Corporation of America Holdings Business Overview
11.10.3 Laboratory Corporation of America Holdings Acute Lymphoblastic Testing Introduction
11.10.4 Laboratory Corporation of America Holdings Revenue in Acute Lymphoblastic Testing Business (2018-2023)
11.10.5 Laboratory Corporation of America Holdings Recent Development
11.11 ARUP Lab
11.11.1 ARUP Lab Company Detail
11.11.2 ARUP Lab Business Overview
11.11.3 ARUP Lab Acute Lymphoblastic Testing Introduction
11.11.4 ARUP Lab Revenue in Acute Lymphoblastic Testing Business (2018-2023)
11.11.5 ARUP Lab Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details